GLP-1 agonist

Comparing Weight Loss Drugs in 2024

Ozempic and Mounjaro are highly effective at treating obesity, however there are many other approved and off-label options that also work.

New obesity drugs target more than just GLP-1 and do much more than suppress appetite for a more nuanced approach to weight loss.

White or Asian younger women who use metformin and have lower sugar and lipid levels tend to experience more weight loss with Mounjaro.

Orforglipron, Semaglutide, and Danuglipron are oral GLP-1 agonists that are all similar enough that cost may end up being the winning factor.

Eli Lilly’s retatrutide has shown stronger weight loss effects than others we’ve seen so far. However, it may have additional heart risks.

The current evidence suggests that GLP-1 agonists do not cause suicidal thoughts. In fact, they may actually be beneficial for depression.

Pfizer’s danuglipron may give Ozempic a run for its money, however has not proven itself to be as effective as Wegovy for weight loss.

Research shows that Ozempic and Wegovy aid in weight loss for about a year. However, despite continued usage, weight regain is common.

Using low-fat diets or consuming too many sweet foods can potentially reduce the effectiveness of Ozempic or Wegovy.

Berberine doesn’t share any similarities with Ozempic, except for the fact that it can moderately help with blood sugar control.

The shortage of Ozempic has led to many compounding pharmacies using a knock-off version of semaglutide that has not been FDA approved.

Newer GLP-1 agonists like Ozempic and Wegovy may increase thyroid cancer risks significantly more than what the current evidence shows.